Leica Microsystems GmbH and Abbott have reached an agreement for Abbott to supply fluorescence in situ hybridisation (FISH) probes that target the HER2 gene locus. The probes
will be used to develop a fully automated FISH solution for HER2 testing on the Leica Microsystems’ BOND, an automated advanced staining platform. Abbott’s PathVysion FISH assay is the gold standard ISH (in situ hybridisation) test for diagnosing the response of patients to Herceptin. Leica Microsystems will develop an automated version of this test to be performed on their BOND system using a standard protocol. Automation of the test on the Leica BOND system will enable Pathology
laboratories to run this diagnostic test more efficiently. The HER2 FISH test is designed to identify patients that are likely to respond to Herceptin, a drug which is used as a frontline therapy for treatment of breast cancer.
Related Stories
-
Most Read Stories
Polls
Loading ...